Immunome (NASDAQ:IMNM) Research Coverage Started at Guggenheim

Equities research analysts at Guggenheim began coverage on shares of Immunome (NASDAQ:IMNM) in a note issued to investors on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $35.00 price target on the stock. Guggenheim’s target price indicates a potential upside of 90.22% from the company’s current price.

A number of other research firms also recently commented on IMNM. Leerink Partnrs reaffirmed an “outperform” rating on shares of Immunome in a report on Monday, January 29th. SVB Leerink began coverage on Immunome in a report on Monday, January 29th. They issued an “outperform” rating and a $30.00 price target for the company. Finally, Wedbush boosted their price target on Immunome from $27.00 to $33.00 and gave the company an “outperform” rating in a report on Monday, April 1st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $32.67.

Immunome Stock Down 2.4 %

Immunome stock opened at $18.40 on Monday. Immunome has a 52 week low of $4.44 and a 52 week high of $30.96. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -3.41 and a beta of 1.66. The stock has a 50-day moving average price of $23.31 and a 200 day moving average price of $14.78.

Institutional Trading of Immunome

A number of institutional investors and hedge funds have recently made changes to their positions in IMNM. Vanguard Group Inc. increased its position in shares of Immunome by 339.0% in the fourth quarter. Vanguard Group Inc. now owns 1,740,026 shares of the company’s stock valued at $18,618,000 after buying an additional 1,343,697 shares in the last quarter. Avidity Partners Management LP purchased a new stake in shares of Immunome in the fourth quarter valued at approximately $14,268,000. Price T Rowe Associates Inc. MD increased its position in shares of Immunome by 505.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,051,222 shares of the company’s stock valued at $11,249,000 after buying an additional 877,592 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Immunome in the second quarter valued at approximately $3,307,000. Finally, TD Asset Management Inc purchased a new stake in shares of Immunome in the third quarter valued at approximately $1,063,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.